0JQ2.LKALA BIO, Inc.

Acerca de

Kala Bio, Inc. operates as a biopharmaceutical enterprise focused on developing and bringing to market innovative treatments. The company employs its unique, proprietary nanoparticle technology, designed to effectively penetrate mucus barriers. Initially, its efforts are concentrated on addressing various ocular conditions. Established in 2009 by founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, the firm maintains its headquarters in Arlington, Massachusetts.

www.kalarx.com

Estadísticas clave

Cap. de mercado

254.16K

BPA

-165.50

Rend. dividendo

0.00%

Beta

-2.41

P/VC

0.64

ROE

-385.6%

Sector

Healthcare

Industria

Biotechnology

CEO

Avi Minkowitz

Empleados

38

Fecha IPO

2018-01-29

País

US